LJAC
RARE icon

L.J. Altfest & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

L.J. Altfest & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,565
Closed -$254K – 358
2024
Q3 		$254K Buy
+4,565
New +$233K 0.03% 295

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

L.J. Altfest & Co's RARE Position: Q4 2024 in Review

L.J. Altfest & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 4,565 shares — an estimated $254K sold.

L.J. Altfest & Co first reported a position in RARE in Q3 2024 and held it in 1 quarter. The position peaked at $254K in Q3 2024. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • L.J. Altfest & Co reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • L.J. Altfest & Co sold 4,565 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $254K.
  • L.J. Altfest & Co first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 1 quarter.
  • L.J. Altfest & Co's Ultragenyx Pharmaceutical position peaked at $254K in Q3 2024.
  • 312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on L.J. Altfest & Co's 13F filing for Q4 2024, filed 7 Feb 2025.